The news is directly about ALX Oncology Holdings. The Overweight rating suggests that the analyst expects the stock to outperform, which could be positive for the stock. However, the lowering of the price target could be seen as a negative signal, suggesting that the analyst expects less upside than before. The net impact is likely to be neutral in the short term.